Kamada (XTAE:KMDA) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:KMDA Kamada Ltd XTAE:KMDA
84 GF Score
Price ₪21.80
GF Value ₪25.14
Valuation Modestly Undervalued
View Full Analysis

What is Kamada Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

XTAE:KMDA
84GF Score
Kamada Ltd XTAE:KMDA
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kamada (XTAE:KMDA) Overvalued in 2026?

Based on GuruFocus' analysis, Kamada stock appears to be undervalued. The current stock price of ₪21.80 is trading 13.3% below its estimated GF Value™ of ₪25.14. GuruFocus considers Kamada to be Modestly Undervalued.

Key valuation signals for XTAE:KMDA:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: ₪25.14 vs. price of ₪21.80 (13.3% below fair value)
  • GF Score™: 84/100

No single metric tells the full story. See the XTAE:KMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kamada Business Description

Other Exchanges KMDA:USA
Address 2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
84GF Score

Get the complete analysis for XTAE:KMDA

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪21.80
Price
₪25.14
GF Value